Transition Therapeutics says Alzheimer's drug effective in sub-group

Thu Oct 15, 2015 6:15am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Oct 15 (Reuters) - Dug developer Transition Therapeutics Inc said detailed data analysis of a study of its experimental drug showed it would benefit a group of Alzheimer's patients.

The company said on Thursday its drug was significantly effective in treating patients with severe agitation and aggression. (Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian)